Antithrombin supplementation for anticoagulation during continuous hemofiltration in critically ill patients with septic shock: A case-control study

Critical Care

Volumn 10, Issue 2, 2006, Pages

  du Cheyron, Damien ^a   Bouchet, Bruno ^a   Bruel, Cédric ^b   Daubin, Cédric ^a   Ramakers, Michel ^a   Charbonneau, Pierre ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACLOTINE; ANTITHROMBIN III; HEPARIN; UNCLASSIFIED DRUG; VASOACTIVE AGENT; ANTICOAGULANT AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTITHROMBIN III DEFICIENCY; ARTICLE; ARTIFICIAL VENTILATION; BLEEDING; BLOOD CLOTTING DISORDER; BLOOD FILTER; CASE CONTROL STUDY; CONTINUOUS HEMODIAFILTRATION; CONTINUOUS HEMOFILTRATION; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG COST; DRUG HALF LIFE; FEMALE; FEMORAL ARTERY; HOSPITAL COST; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SCORING SYSTEM; SEPTIC SHOCK; SINGLE DRUG DOSE; SURVIVAL TIME; ULTRAFILTRATION; VASCULAR ACCESS; COHORT ANALYSIS; COMPARATIVE STUDY; CRITICAL ILLNESS; HEMOFILTRATION; MIDDLE AGED; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; SURVIVAL;

ADULT; AGED; ANTICOAGULANTS; ANTITHROMBIN III; CASE-CONTROL STUDIES; COHORT STUDIES; CRITICAL ILLNESS; FEMALE; HEMOFILTRATION; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL ANALYSIS;

EID: 34247638669     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc4853     Document Type: Article

References (29)

1. Annane D Aegerter P Jars-Guincestre MC Guidet B Current epidemiology of septic shock: The CUB-Rea Network Am J Respir Crit Care Med 2003 168 165-172 10.1164/rccm.2201087 12851245
2. Balk RA The systemic inflammatory response syndrome JAMA 1995 274 127 10.1001/jama.274.2.127b 7595995
3. Seitz R Wolf M Egbring R Havemann K The disturbance of hemostasis in septic shock: Role of neutrophil elastase and thrombin, effects of antithrombin III and plasma substitution Eur J Haematol 1989 43 22-28 2788582
4. Wilson RF Mammen EF Robson MC Heggers JP Soullier G DePoli PA Antithrombin, prekallikrein, and fibronectin levels in surgical patients Arch Surg 1986 121 635-640 3486649
5. Fourrier F Chopin C Goudemand J Hendrycx S Caron C Rime A Marey A Lestavel P Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies Chest 1992 101 816-823 1531791
6. Lorente JA Garcia-Frade LJ Landin L de Pablo R Torrado C Renes E Garcia-Avello A Time course of hemostatic abnormalities in sepsis and its relation to outcome Chest 1993 103 1536-1542 8486040
7. Kinasewitz GT Yan SB Basson B Comp P Russell JA Cariou A Um SL Utterback B Laterre PF Dhainaut JF Universal changes in biomarkers of coagulation and inflammation occur in patients with severe sepsis, regardless of causative micro-organism [ISRCTN74215569] Crit Care 2004 8 R82-R90 420030 15025782 10.1186/cc2459
8. Salmon J Cardigan R Mackie I Cohen SL Machin S Singer M Continuous venovenous haemofiltration using polyacrylonitrile filters does not activate contact system and intrinsic coagulation pathways Intensive Care Med 1997 23 38-43 10.1007/s001340050288 9037638
9. Singer M McNally T Screaton G Mackie I Machin S Cohen SL Heparin clearance during continuous veno-venous haemofiltration Intensive Care Med 1994 20 212-215 10.1007/BF01704703 8014289
10. Williams MR D'Ambra AB Beck JR Spanier TB Morales DL Helman DN Oz MC A randomized trial of antithrombin concentrate for treatment of heparin resistance Ann Thorac Surg 2000 70 873-877 10.1016/S0003-4975(00)01550-2 11016326
11. Anonymous American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Crit Care Med 1992 20 864-874 1597042
12. Taylor FB Jr Toh CH Hoots WK Wada H Levi M Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation Thromb Haemost 2001 86 1327-1330 11816725
13. Le Gall JR Lemeshow S Saulnier F A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study JAMA 1993 270 2957-2963 10.1001/jama.270.24.2957 8254858
14. Vincent JL Moreno R Takala J Willatts S De Mendonca A Bruining H Reinhart CK Suter PM Thijs LG The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine Intensive Care Med 1996 22 707-710 8844239
15. Ilias W List W Decruyenaere J Lignian H Knaub S Schindel F Keinecke HO Heinrichs H Thijs LG Antithrombin III in patients with severe sepsis: A pharmacokinetic study Intensive Care Med 2000 26 704-715 10.1007/ s001340051236 10945387
16. Kellum JA Mehta RL Angus DC Palevsky P Ronco C The first international consensus conference on continuous renal replacement therapy Kidney Int 2002 62 1855-1863 10.1046/j.1523-1755.2002.00613.x 12371989
17. Kozek-Langenecker SA Kettner SC Oismueller C Gonano C Speiser W Zimpfer M Anticoagulation with prostaglandin E1 and unfractionated heparin during continuous venovenous hemofiltration Crit Care Med 1998 26 1208-1212 10.1097/00003246-199807000-00021 9671370
18. Shulman RI Singer M Rock J Continuous renal replacement therapy. Keeping the circuit open: Lessons from the lab Blood Purif 2002 20 275-281 10.1159/000047020 11867875
19. Zimmerman JL Use of blood products in sepsis: An evidence-based review Crit Care Med 2004 32 S542-S547 10.1097/01.CCM.0000145906.63859.1A 15542962
20. Kutsogiannis DJ Gibney RT Stollery D Gao J Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients Kidney Int 2005 67 2361-2367 10.1111/ j.1523-1755.2005.00342.x 15882280
21. Bastien O French P Paulus S Filley S Berruyer M Dechavanne M Estanove S Antithrombin III deficiency during continuous venovenous hemodialysis Contrib Nephrol 1995 116 154-158 8529370
22. Fourrier F Jourdain M Tournoys A Clinical trial results with antithrombin III in sepsis Crit Care Med 2000 28 S38-S43 10.1097/ 00003246-200009001-00009 11007196
23. Eisele B Lamy M Thijs LG Keinecke HO Schuster HP Matthias FR Fourrier F Heinrichs H Delvos U Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis Intensive Care Med 1998 24 663-672 10.1007/s001340050642 9722035
24. Warren BL Eid A Singer P Pillay SS Carl P Novak I Chalupa P Atherstone A Penzes I Kubler A Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial Jama 2001 286 1869-1878 10.1001/jama.286.15.1869 11597289
25. Levy JH Despotis GJ Szlam F Olson P Meeker D Weisinger A Recombinant human transgenic antithrombin in cardiac surgery: A dose-finding study Anesthesiology 2002 96 1095-1102 10.1097/00000542-200205000-00011 11981148
26. Lemmer JH Jr Despotis GJ Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery J Thorac Cardiovasc Surg 2002 123 213-217 10.1067/mtc.2002.119060 11828278
27. Avidan MS Levy JH Scholz J Delphin E Rosseel PM Howie MB Gratz I Bush CR Skubas N Aldea GS A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass Anesthesiology 2005 102 276-284 10.1097/00000542-200502000-00007 15681940
28. Lima EQ Dirce MT Castro I Yu L Mortality risk factors and validation of severity scoring systems in critically ill patients with acute renal failure Ren Fail 2005 27 547-556 10.1080/08860220500198771 16152992
29. Ronco C Bellomo R Homel P Brendolan A Dan M Piccinni P La Greca G Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: A prospective randomised trial Lancet 2000 356 26-30 10.1016/S0140-6736(00)02430-2 10892761